Fatty Liver News and Research

Latest Fatty Liver News and Research

Isomaltulose more suitable than table sugar for people with type 2 diabetes

Potsdam-Rehbruecke - Like sucrose (table sugar), the natural disaccharide isomaltulose (PalatinoseTM) consists of glucose and fructose, but it is apparently more suitable for people with type 2 diabetes with regard to regulating blood glucose levels.

17 Feb 2016

Aerobic exercise may prevent alcohol-related liver damage

According to the Centers for Disease Control and Prevention, excessive alcohol use is responsible for more than 80,000 deaths in the United States each year. Over time, excessive drinking can lead to several chronic conditions, such as fatty liver disease and cirrhosis.

16 Feb 2016

Alcohol appears to impair the body's ability to keep gut bacteria in check

Alcohol itself can directly damage liver cells. Now researchers at University of California, San Diego School of Medicine report evidence that alcohol is also harmful to the liver for a second reason — it allows gut bacteria to migrate to the liver, promoting alcohol-induced liver disease.

11 Feb 2016

UC San Diego School of Medicine launches new NAFLD Research Center

Roughly one-quarter of all Americans - an estimated 100 million adults and children - have nonalcoholic fatty liver disease (NAFLD), a chronic condition that can lead to cirrhosis, liver cancer and liver failure.

9 Feb 2016

Incidence and severity emerging CVD risk factors may differ between genders

The incidence and severity of both traditional and emerging cardiovascular disease (CVD) risk factors as well as the response to treatment may differ between genders. In this narrative review, several emerging CVD risk factors (i.e. inflammatory and haemostatic markers, endothelial dysfunction, homocysteine, lipid disorders, microalbuminuria/proteinuria, coronary artery calcium score, arterial stiffness, periodontitis, inflammatory bowel syndrome, obstructive sleep apnea, impaired glucose metabolism, metabolic syndrome and non-alcoholic fatty liver disease) are discussed in the context of gender differences.

5 Feb 2016

Potential treatment target identified for fatty liver disease

Two proteins, p38 gamma and p38 delta, control the accumulation of fat in the liver, a process linked to the development of insulin resistance and diabetes, which are common outcomes of obesity. These findings are presented in an article published by researchers at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC).

4 Feb 2016

Scientists reveal why non-alcoholic steatohepatitis worsens in obese people

In results published on October 19, 2015 in the Journal of Lipid Research, a team of translational scientists at the Medical University of South Carolina report a new reason why non-alcoholic steatohepatitis (NASH) worsens in people who are obese.

20 Jan 2016

Scientists identify unusual regulator of body weight, metabolic syndrome

Scientists at the Gladstone Institutes have discovered an unusual regulator of body weight and the metabolic syndrome: a molecular mechanism more commonly associated with brain cells. Lowering levels of P75 neurotrophin receptor (NTR)--a receptor involved in neuron growth and survival--protected mice fed a high-fat diet from developing obesity, diabetes, and fatty liver disease.

12 Jan 2016

GPR119 could be a potential treatment target for nonalcoholic fatty liver disease

New research published in the January 2016 issue of The FASEB Journal suggests that the G-protein-coupled receptor 119 (GPR119) could be a viable treatment target for nonalcoholic fatty liver disease. This receptor has already been identified as a drug target for diabetes and obesity, and this report raises hopes that compounds that target GPR119 for diabetes or obesity might also work for non-alcoholic fatty liver disease.

12 Jan 2016

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

DURECT Corporation today announced the successful completion of a Phase 1 clinical trial with an injectable formulation of DUR-928 intended for acute use indications. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and in acute organ injuries such as acute kidney injury (AKI).

6 Jan 2016

Novel antibody improves glucose regulation and reduces fatty liver in obese mice

A new study by researchers from Harvard T.H. Chan School of Public Health and colleagues describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases.

24 Dec 2015

Regulus begins RG-125(AZD4076) Phase I study for treatment of NASH in patients with type 2 diabetes/pre-diabetes

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-125(AZD4076), by its collaboration partner AstraZeneca.

21 Dec 2015

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation of the active pharmaceutical ingredient DS102 (15-HEPE) which is being explored for the treatment of fatty liver disorders, such as non-alcoholic steatohepatitis (NASH) and pulmonary disorders, such as idiopathic pulmonary fibrosis (IPF).

18 Dec 2015

Chronic alcohol use with repeated binge drinking can cause more damage to the liver

Excessive alcohol consumption is a global public health issue. In the United States, binge drinking is the most common form - so common, in fact, that the Centers for Disease Control and Prevention reports approximately one in six adults binge drinks about four times each month.

18 Dec 2015

Bile acid may help treat fatty liver disease and obesity

A bile acid that can turn off a receptor in the gut has prevented and reversed fatty liver disease in mice, according to an international team of researchers. The compound may help treat certain metabolic disorders, such as Type 2 diabetes and obesity, as well.

16 Dec 2015

Researchers reveal new technique to grow human hepatocytes in the laboratory

In new research appearing in the prestigious journal Nature Biotechnology, an international research team led by The Hebrew University of Jerusalem describes a new technique for growing human hepatocytes in the laboratory. This groundbreaking development could help advance a variety of liver-related research and applications, from studying drug toxicity to creating bio-artificial liver support for patients awaiting transplantations.

27 Nov 2015

Obese children with NAFLD not meeting recommended physical activity levels

In a new study published today in the journal Nutrients, research from the University of Surrey and the Children's Liver Disease Foundation has found that both obese children and those with Non-Alcoholic Fatty Liver Disease (NAFLD) are not meeting the UK recommendations for a variety of vitamins and minerals.

26 Nov 2015

Type II diabetes drug can effectively clear fatty liver disease from some patients

New research published in The Lancet has shown that a drug, currently used in the treatment of Type II diabetes, can be effective in clearing fatty liver disease from some patients.

20 Nov 2015

Potential treatment strategy for glycogen storage disease

Researchers from the Duke-NUS Graduate Medical School Singapore and Duke Medicine have identified a potential treatment strategy for an often-fatal inherited glycogen storage disease.

18 Nov 2015

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease.

17 Nov 2015

Fatty Liver News and Research

Latest Fatty Liver News and Research

Isomaltulose more suitable than table sugar for people with type 2 diabetes

Aerobic exercise may prevent alcohol-related liver damage

Alcohol appears to impair the body's ability to keep gut bacteria in check

UC San Diego School of Medicine launches new NAFLD Research Center

Incidence and severity emerging CVD risk factors may differ between genders

Potential treatment target identified for fatty liver disease

Scientists reveal why non-alcoholic steatohepatitis worsens in obese people

Scientists identify unusual regulator of body weight, metabolic syndrome

GPR119 could be a potential treatment target for nonalcoholic fatty liver disease

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

Novel antibody improves glucose regulation and reduces fatty liver in obese mice

Regulus begins RG-125(AZD4076) Phase I study for treatment of NASH in patients with type 2 diabetes/pre-diabetes

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

Chronic alcohol use with repeated binge drinking can cause more damage to the liver

Bile acid may help treat fatty liver disease and obesity

Researchers reveal new technique to grow human hepatocytes in the laboratory

Obese children with NAFLD not meeting recommended physical activity levels

Type II diabetes drug can effectively clear fatty liver disease from some patients

Potential treatment strategy for glycogen storage disease

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Fatty Liver News and Research

Latest Fatty Liver News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in